Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) including Src and Lyn, spleen tyrosine kinase (SYK), and bruton’s tyrosine kinase (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Elgamal, Ola A., Mehmood, Abeera, Jeon, Jae Yoon, Carmichael, Bridget, Lehman, Amy, Orwick, Shelley J., Truxall, Jean, Goettl, Virginia M., Wasmuth, Ronni, Tran, Minh, Mitchell, Shaneice, Lapalombella, Rosa, Eathiraj, Sudharshan, Schwartz, Brian, Stegmaier, Kimberly, Baker, Sharyn D., Hertlein, Erin, Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988309/
https://www.ncbi.nlm.nih.gov/pubmed/31992353
http://dx.doi.org/10.1186/s13045-019-0821-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988309/
https://www.ncbi.nlm.nih.gov/pubmed/31992353
http://dx.doi.org/10.1186/s13045-019-0821-7

Ejemplares similares